Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 26, 2007

BioLineRx In-Licenses Two Drug Candidates from Yeda Research and Development

  • BioLineRx signed in-license agreements to develop and commercialize two new therapeutic candidates: BL-3040, a small molecule for the treatment of estrogen-regulated malignancies and osteoporosis and BL-3050, a protein complex for the treatment of atherosclerosis.

    This marks the third and fourth in-licensing agreements signed by BioLineRx since its IPO in February 2007, bringing the total number of drugs under development by the company to 14.

    The worldwide, exclusive license agreements were signed with Yeda Research and Development, the technology transfer company of the Weizmann Institute of Science.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »